Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab

Journal of Clinical Endocrinology and Metabolism

Volumn 101, Issue 11, 2016, Pages 4431-4439

  De Filette, Jeroen ^a   Jansen, Yanina ^a   Schreuer, Max ^a   Everaert, Hendrik ^b   Velkeniers, Brigitte ^a   Neyns, Bart ^a   Bravenboer, Bert ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; FLUORODEOXYGLUCOSE F 18; IPILIMUMAB; LEVOTHYROXINE; PEMBROLIZUMAB; PROPRANOLOL; TECHNETIUM 99M; THIONAMIDE; THYROID ANTIBODY; THYROTROPIN; THYROXINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CENTER; CANCER PATIENT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG UPTAKE; FEMALE; FUNCTIONAL ASSESSMENT; HEALTH CARE ACCESS; HEALTH PROGRAM; HUMAN; HYPOTHYROIDISM; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MELANOMA; PATIENT MONITORING; PET-CT SCANNER; PRIORITY JOURNAL; PROSPECTIVE STUDY; THYROID DISEASE; THYROID FUNCTION; THYROIDITIS; THYROTOXICOSIS; BLOOD; CHEMICALLY INDUCED; DIAGNOSTIC IMAGING; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; HYPOTHYROIDISM; MALE; MELANOMA; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; THYROIDITIS; THYROTOXICOSIS;

EID: 84994852309     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2016-2300     Document Type: Article

References (36)

1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252-264.
2. Ryder M, Callahan M, Postow MA, Wolchok J, Fagin JA. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer. 2014;21:371-381.
3. Corsello SM, Barnabei A, Marchetti P, De Vecchis L, Salvatori R, Torino F. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab. 2013;98:1361-1375.
4. U.S. Food and Drug Administration. Pembrolizumab. http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm412861.htm.Updated January 9, 2015. Accessed December 12, 2015.
5. European Medicines Agency. Keytruda-pembrolizumab. http://www.ema.europa.eu/ema/index.jsp?curl-pages/medicines/human/medicines/003820/human-med-001886.jsp&mid-WC0b01ac05 8001d124. Accessed April 30, 2016.
6. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer.NEngl J Med. 2015;372:2018-2028.
7. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540-1550.
8. Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16:908-918.
9. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521-2532.
10. Delivanis D, Merten MM, Kottschade L, Ryder M. Immune therapies targeting the thyroid: new insights from a comprehensive review of pembrolizumab-induced thyroiditis cases at Mayo Clinic. Presented at 85th Annual Meeting of the American Thyroid Association: Lake Buena Vista, FL; October 20, 2015. Abstract 88.
11. Orlov S, Salari F, Kashat L, Walfish PG. Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies. J Clin Endocrinol Metab. 2015;100:1738-1741.
12. Jansen Y, Schreuer M, Seremet T, Awada G, Wilgenhof S, Neyns B. Single-center experience with pembrolizumab in patients with ipilimumab pretreated advanced melanoma. In: Proceedings of European Association of Dermato Oncology; October 29, 2015; Marseille, France. Abstract.
13. Jansen Y, Corthals J, Wilgenhof S, et al. A randomized controlled phase II clinical trial on autologous monocyte-derived mRNA electroporated dendritic cells for stage III/IV melanoma patientswhoare disease-free following the local treatment of macrometastases. In: Proceedings of Society for Melanoma Research International Congress; November 18-21, 2015; San Francisco, CA. Abstract.
14. American Joint Committee on Cancer. AJCC Cancer Staging Manual. In: Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. 7th ed. New York, Dordrecht, Heidelberg, London: Springer; 2010.
15. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655.
16. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412-7420.
17. U.S. Food and Drug Administration. Keytruda (pembrolizumab). Risk Evaluation and Mitigation Strategy (REMS) Review. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2014/125514Orig1s000RiskR.pdf. Published July 25, 2014. Accessed February 11, 2016.
18. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.03. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-8.5x11.pdf. Published June 14, 2010. Accessed December 16, 2015.
19. Schreuer M, Meersseman G, Van Den Herrewegen S, et al. Quantitative assessment ofBRAFV600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors. J Transl Med. 2016; 14:95.
20. Fellner C. Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tagmaylimit its use.PT. 2012;37:503-530.
21. Chen W, Parsons M, Torigian DA, Zhuang H, Alavi A. Evaluation of thyroid FDG uptake incidentally identified on FDG-PET/CT imaging. Nucl Med Commun. 2009;30:240-244.
22. Karantanis D, Bogsrud TV, Wiseman GA, et al. Clinical significance of diffusely increased 18F-FDG uptake in the thyroid gland. J Nucl Med. 2007;48:896-901.
23. Chen YK, Chen YL, Liao AC, Shen YY, Kao CH. Elevated 18F-FDG uptake in skeletal muscles and thymus: a clue for the diagnosis of Graves' disease. Nucl Med Commun. 2004;25:115-121.
24. van Kooten MJ, van den Berg G, Glaudemans AW, Hiltermann TJ, Groen HJ, Links TP. Transient thyrotoxicosis during nivolumab treatment. Poster presented at ENDO2016, April 3, 2016; Boston, MA. https://endo.confex.com/endo/2016endo/webprogram/Paper25877.html. Accessed April 6, 2016.
25. Caturegli P, De Remigis A, Rose NR. Hashimoto thyroiditis: clinical and diagnostic criteria. Autoimmun Rev. 2014;13:391-397.
26. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23-34.
27. Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11:155-164.
28. Rhee CM, Bhan I, Alexander EK, Brunelli SM. Association between iodinated contrast media exposure and incident hyperthyroidism and hypothyroidism. Arch Intern Med. 2012;172:153-159.
29. Leger AF, Massin JP, Laurent MF, et al. Iodine-induced thyrotoxicosis: analysis of eighty-five consecutive cases. Eur J Clin Invest. 1984;14:449-455.
30. Skare S, Frey HM. Iodine induced thyrotoxicosis in apparently normal thyroid glands. Acta Endocrinol (Copenh). 1980;94:332-336.
31. Fradkin JE, Wolff J. Iodide-induced thyrotoxicosis. Medicine (Baltimore). 1983;62:1-20.
32. Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 2007;19:813-824.
33. Abbas AK, Lichtman AH, Pillai S. Cellular and Molecular Immunology. 8th ed. Philadelphia, PA: Elsevier Saunders; 2014.
34. Yoshida H, Amino N, Yagawa K, et al. Association of serum antithyroid antibodies with lymphocytic infiltration of the thyroid gland: studies of seventy autopsied cases. J Clin Endocrinol Metab. 1978;46:859-862.
35. Huber G, Staub JJ, Meier C, et al. Prospective study of the spontaneous course of subclinical hypothyroidism: prognostic value of thyrotropin, thyroid reserve, and thyroid antibodies. J Clin Endocrinol Metab. 2002;87:3221-3226.
36. Davies AM, Sutton BJ. Human IgG4: a structural perspective. Immunol Rev. 2015;268:139-159.